J&J unit to start mid-stage COVID-19 vaccine trials in Spain
Sep 15 2020
He tweeted: "Good news for everyone, the Oxford vaccine trials are back up and running".
The World Health Organization has named the vaccine being developed by AstraZeneca in partnership with the University of Oxford as probably the most promising in the world and the most advanced in terms of development.
Around 18,000 participants have had AZD1222 as part of the trial, AZ said.
Together with the AstraZeneca vaccine, it is on the list of WHO-monitored list of candidate vaccines on a quest to get approved for industrial production once they complete all three required phases of clinical trials.
But Oxford University today said an independent review process involving the United Kingdom medical regulator has concluded and trials will recommence. All routine follow-up appointments continued as normal during this period.
The AstraZeneca statement said information about the illness the woman suffered can not be disclosed.
The Oxford University's Jenner Institute team started working to develop a vaccine against the SARS-CoV-2, or the virus which causes COVID-19 in January this year and says it has been working with unprecedented urgency in a race against the coronavirus.
A phase III trial of a COVID-19 inactivated vaccine developed by Chinese state-owned pharmaceutical company Sinopham began in the UAE in July and is yet to be completed.
An independent committee will review the study's safety data before deciding whether the research will continue or not.
All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards, AstraZeneca said. More than 30 Europe-based experts signed an open letter this week publicly voicing their suspicion about the vaccine study, specifically noting "potential data inconsistencies". He had earlier predicted that if the coronavirus shot is a two-dose vaccine, as is the case with measles or rotavirus, then the world would require 15 billion doses.
"And only trials such as this will be able to tell us that". The trial was swiftly restarted after investigations determined the illness was not related to the vaccine.
The fact that some pharmaceutical companies delegate the risks associated with their vaccines to countries which buy them raises additional questions, the RDIF chief said.